- Home
- QCOM vs ABBV Comparison
QCOM vs ABBV Comparison
Compare QCOM & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QCOM | ABBV |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.9B | 400.9B |
| IPO Year | 2009 | 2012 |
Fundamental Metrics
Financial Performance| Metric | QCOM | ABBV |
|---|---|---|
| Price | $129.41 | $221.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 19 |
| Target Price | $167.35 | ★ $247.06 |
| AVG Volume (30 Days) | ★ 7.8M | 5.1M |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | 2.74% | ★ 3.15% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | 2.36 |
| Revenue | $44,284,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $1.03 | $11.90 |
| Revenue Next Year | $0.76 | $8.24 |
| P/E Ratio | ★ $46.69 | $93.12 |
| Revenue Growth | ★ 13.66 | 8.57 |
| 52 Week Low | $120.80 | $164.39 |
| 52 Week High | $205.55 | $244.81 |
Technical Indicators
Market Signals| Indicator | QCOM | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 28.62 | 43.25 |
| Support Level | N/A | $220.11 |
| Resistance Level | $163.23 | $231.00 |
| Average True Range (ATR) | 3.23 | 5.23 |
| MACD | -0.46 | -1.30 |
| Stochastic Oscillator | 2.63 | 14.15 |
Price Performance
Historical ComparisonAbout QCOM QUALCOMM Incorporated
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.